FDA Class II Recall: Aurolife Pharma's Discolored Clorazepate Dipotassium Tablets Impact Supply
Aurolife Pharma LLC faces an FDA Class II recall for 6,909 bottles of Clorazepate Dipotassium Tablets due to discoloration. This event, initiated by distributor Aurobindo Pharma USA Inc., signals critical quality control deficiencies. Procurement and regulatory teams must assess supply chain exposure and accelerate alternative sourcing strategies to mitigate potential market disruption for this essential benzodiazepine.
FDA Class II Recall: Aurolife Pharma's Discolored Clorazepate Dipotassium Tablets
The U.S. Food and Drug Administration (FDA) has classified an ongoing recall of Clorazepate Dipotassium Tablets, USP, 7.5 mg, manufactured by Aurolife Pharma LLC, as Class II. This voluntary, firm-initiated recall (D-0492-2024) was prompted by significant quality concerns: the tablets exhibited discoloration, specifically described as "dotted and yellow spots." The recall, initiated on April 24, 2024, by Aurobindo Pharma USA Inc., the product's distributor, affects a substantial volume of 6,909 bottles distributed nationwide across the USA. Specifically, the affected lots include CZB124001B, CZB124002B, and CZB124003B (100 tablets per bottle, NDC 13107-283-01), and CZB124001A and CZB124003A (500 tablets per bottle, NDC 13107-283-05), all with an expiration date of December 31, 2025. For procurement directors and supply chain VPs, this event underscores the critical importance of robust incoming material inspection and supplier quality agreements. A Class II recall indicates that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates immediate action to quarantine affected inventory and assess the continuity of supply for this critical central nervous system depressant.
Global Supply Chain Implications: Aurolife Pharma's Manufacturing and Aurobindo's Distribution
The recall highlights the complexities of global pharmaceutical supply chains, with Aurolife Pharma LLC identified as the manufacturer and Aurobindo Pharma USA Inc. as the U.S. distributor. While Aurobindo Pharma USA Inc. operates from East Windsor, NJ, the product description explicitly states "Made in India," indicating an international manufacturing origin for the Clorazepate Dipotassium tablets. This geographical separation between manufacturing and distribution points introduces additional layers of oversight and risk. For regulatory affairs heads, ensuring consistent quality across international manufacturing sites and through the entire distribution network is paramount. The discoloration issue points to potential lapses in manufacturing process control, raw material quality, or storage conditions at the point of origin. Business development executives must recognize that such quality incidents can erode trust and impact market access, even for established molecules like Clorazepate Dipotassium. Companies relying on multi-national supply chains must implement stringent vendor qualification programs that extend beyond initial audits to continuous monitoring of manufacturing practices, environmental controls, and transportation conditions to prevent similar quality deviations from reaching the market.
Commercial Impact and Supply Vulnerability for Clorazepate Dipotassium
The recall of 6,909 bottles of Clorazepate Dipotassium Tablets represents a tangible disruption to the supply of this benzodiazepine, prescribed for anxiety and certain seizure disorders. For procurement directors, the immediate concern is the availability of alternative stock and the potential for short-term supply shortages, particularly for the 7.5 mg dosage strength. While the recall is classified as Class II, any interruption in the supply of a widely used prescription drug can impact patient care and create significant operational challenges for pharmacies and healthcare systems. Supply chain VPs must quickly quantify their exposure to Aurolife Pharma LLC's Clorazepate Dipotassium and assess the lead times for securing replacement inventory from qualified alternative sources. The nationwide distribution pattern means the impact is not geographically isolated, necessitating a broad market response. This event serves as a critical reminder for all stakeholders to maintain diversified sourcing strategies and to avoid over-reliance on single manufacturers, even for generic products where multiple suppliers typically exist. The financial implications extend beyond the cost of returned goods to potential lost sales and reputational damage for distributors and downstream formulators.
Strategic Sourcing: Mitigating Risk with Alternative Pharmaceutical Suppliers
In light of the Aurolife Pharma LLC recall, procurement teams must prioritize identifying and qualifying alternative suppliers for Clorazepate Dipotassium. Given the absence of specific alternative suppliers in the current intelligence, a proactive, systematic approach is essential. This involves mapping the global supply landscape for benzodiazepine APIs and finished dosage forms, focusing on manufacturers with robust quality management systems and a strong regulatory compliance history. Diversifying the supplier base across different geographical regions can significantly reduce exposure to single-point failures, whether due to quality issues, geopolitical events, or logistical disruptions. Qualification timelines for new pharmaceutical suppliers can be extensive, often spanning 12-24 months, encompassing comprehensive audits, analytical testing, and regulatory filing updates. Therefore, business development executives should advocate for strategic partnerships that build resilience rather than solely focusing on cost optimization. Regulatory affairs heads must ensure that any new supplier qualifications meet all FDA requirements, including comparability studies and stability data, to facilitate seamless transitions and maintain product integrity.
Regulatory Scrutiny and Quality System Remediation for Aurolife Pharma
The "ongoing" status of this Class II recall signifies continued FDA oversight and the expectation for comprehensive remediation from both Aurolife Pharma LLC (manufacturer) and Aurobindo Pharma USA Inc. (distributor). Regulatory affairs heads understand that the FDA will require a thorough root cause analysis of the discoloration issue, followed by the implementation of robust corrective and preventive actions (CAPA). This typically involves investigating raw material specifications, manufacturing process parameters, environmental controls, and packaging integrity. Failure to adequately address the underlying quality system deficiencies could lead to escalated regulatory actions, including potential Warning Letters, import alerts, or even consent decrees. For companies sourcing from Aurolife Pharma LLC, this event necessitates a re-evaluation of their supplier audit schedules and performance metrics. Business development executives should be aware that a manufacturer's regulatory compliance record directly impacts their ability to secure new contracts and maintain existing market share, making proactive quality investments a commercial imperative. The recall serves as a clear signal that the FDA maintains a vigilant stance on product quality, irrespective of a product's generic status.
Broader Industry Quality Trends and Compliance Imperatives
This Class II recall of Clorazepate Dipotassium Tablets by Aurolife Pharma LLC is not an isolated incident but rather indicative of broader industry trends concerning pharmaceutical quality and regulatory compliance. Recent parallel events, such as the FDA Class II Recall of Essential Wellness Pharma's Progesterone Injection due to sterility assurance failures, underscore the continuous scrutiny manufacturers face regarding their quality management systems. For regulatory affairs heads, these events highlight the imperative for proactive compliance strategies that go beyond mere adherence to regulations, fostering a culture of quality throughout the organization. Procurement directors and supply chain VPs must integrate regulatory intelligence into their supplier selection and monitoring processes, recognizing that a supplier's compliance history directly impacts supply chain stability. The commercial implications are significant; companies with a strong track record of quality and compliance gain a competitive advantage, while those facing repeated quality issues risk market erosion and severe financial penalties. This ongoing vigilance from the FDA demands that all players in the global chemical and life sciences industry prioritize investment in advanced manufacturing technologies, robust quality control, and continuous personnel training to safeguard product integrity and patient safety.